Description |
BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively.
|
Related Catalog |
|
Target |
HDAC5:0.85 μM (IC50)
HDAC9:1.88 μM (IC50)
|
In Vitro |
BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with BRD4354 having half-maximum inhibitory concentrations (IC50) of 0.85 μM and 1.88 μM, respectively. BRD 4354 also inhibits HDACs 4, 6, 7, and 8 at higher concentrations (3.88-13.8 μM) but demonstrates less of an inhibitory effect on other class I HDACs 1, 2, and 3 (IC50>40 μM) [1].
|
Cell Assay |
A549 adenocarcinoma cells were treated with BRD 4354 for 24 h at 10 μM, and the top 50 upregulated and top 50 down regulated genes are compared to other compound treatments involving drugs, bioactive compounds with established MoA, and novel synthetic compounds[1].
|
References |
[1]. Boskovic ZV, ET AL. Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. ACS Chem Biol. 2016 Jul 15;11(7):1844-51.
|